This week we delve into the latest happenings in the pharma sector with Merck & Ginkgo’s $490M Biologics partnership, Novartis’ BTK Inhibitor receiving the coveted FDA greenlight but raising concerns for competitor drugs, results from Novo’s Cardiovascular therapy trial, and other top news!
Merck has formed a $490 million partnership with Ginkgo Bioworks to advance biologics manufacturing efficiency. The collaboration aims to develop a more streamlined and cost-effective approach to producing biologic drugs. Ginkgo’s platform, which involves designing custom microorganisms for various applications, will be utilized to optimize the manufacturing process. The partnership seeks to address challenges in biologics production and could lead to significant improvements in drug manufacturing processes.
The approval of Novartis’ Bruton’s tyrosine kinase (BTK) inhibitor has sparked concerns about potential risks for Dupixent, a drug developed by Sanofi and Regeneron. Dupixent, used to treat conditions like eczema and asthma, may face competition from Novartis’ BTK inhibitor in treating autoimmune diseases. While BTK inhibitors have shown promise, there are worries about their safety profile. The approval’s impact on Dupixent’s market share and safety comparisons between the two drugs are subjects of interest.
Hims & Hers, a telehealth company, is anticipating the establishment of a weight reduction-focused business by the end of the year. The new initiative will provide personalized solutions for weight management, combining medical expertise and digital health tools. Hims & Hers aims to address the growing demand for accessible and effective weight loss programs, offering convenience through their online platform. The move represents the company’s expansion into broader healthcare services beyond its initial focus.
Sage Therapeutics is expected to undergo downsizing and project scaling following the FDA’s rejection of zuranolone as a treatment for major depressive disorder (MDD). The decision raises uncertainty about the drug’s future prospects and leaves Sage with plans to reduce its workforce. Despite positive results in some trials, the FDA’s concerns over efficacy and dosing led to the rejection. The setback highlights the challenges of developing treatments for mental health disorders and the subsequent impact on the company’s strategic plans.
Novo Nordisk’s Wegovy has demonstrated success in reducing the risk of cardiovascular events in a Phase 3 trial. Wegovy is a GLP-1 receptor agonist designed for weight management. The trial’s positive results reveal its potential to not only aid weight loss but also address cardiovascular risks in individuals with obesity or overweight. This marks a significant advancement in the treatment landscape for obesity-related complications, potentially leading to improved health outcomes for patients at risk of heart-related issues.
Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.